Fused Heterocyclic Morpholines for High-Activity ATR Inhibition

Solution Overview

Problem

There is an urgent need for new ATR kinase inhibitors with high activity and good druggability to target cancer cells, as no ATR kinase inhibitors have been marketed to date, and existing compounds do not fully leverage the vulnerability of cancer cells' reliance on ATR for survival.

Innovation Solution

Development of a substituted fused heterocyclic compound with specific structural features, including various heteroaromatic cyclic groups and substituents, which can be used as an ATR inhibitor, along with a method for its preparation and a pharmaceutical composition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing ATR kinase inhibitors are used, then some inhibitory activity is achieved, but high activity and good druggability are not fully realized

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by systematically varying key structural parameters of the morpholine core compound, including substituent types (R1-R6 groups), ring fusion patterns, and molecular weight parameters. This optimization approach transforms the molecular structure to achieve both high ATR kinase inhibitory activity (IC50 values in nanomolar range) and improved druggability properties such as oral bioavailability and selective toxicity toward cancer cells.

Inventive Principle:
Principle #35Parameter changes

2Object-affected harmful factors

If cancer cells are targeted with ATR inhibitors, then therapeutic efficacy is enhanced, but selective toxicity against normal cells must be maintained

Engineering Contradiction:
Core Design Contradiction:
Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by designing compounds with specific local structural features that interact preferentially with ATR kinase in cancer cells. The substituted morpholine structure with particular substituent patterns (R1-R6 groups including heteroaromatic rings, alkyl chains, and functional groups) creates localized molecular recognition elements that enhance binding affinity to ATR while exploiting the elevated ATR dependence in cancer cells, thereby achieving selective toxicity.

Inventive Principle:
Principle #3Local quality

3Reliability

If new ATR kinase inhibitors are developed, then high activity is achieved, but complexity of compound structure increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the complex ATR kinase inhibitor into modular components: a core morpholine ring system with systematically varied substituents (R1-R6 groups). This modular architecture allows independent optimization of each segment's function - the morpholine core provides ATR binding affinity while substituents contribute to selectivity and pharmacokinetic properties, thereby managing structural complexity through functional modularity.

Inventive Principle:
Principle #1Segmentation

Data Source

PatentUS12435095B2Substituted morpholines as ATR kinase inhibitors
Publication Date: 2025.10.07
  • US12435095B2 patent drawing
  • US12435095B2 patent drawing
  • US12435095B2 patent drawing

AI summary

A substituted fused heterocyclic compound, and a preparation method therefor and the use thereof. Provided is a compound having the structure of formula I or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof can be used as an ATR inhibitor, which has a high activity.